CONSTANCE JACOB: Open Payments
NPI 1639729726 · WICHITA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$57,327 in 303 payments from 13 companies in 2025. Trend: 2023 $2,965 · 2024 $2,778 · 2025 $57,327
Speaker / faculty: $41,786Consulting: $6,056Food & beverage: $5,428Travel & lodging: $4,057
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 111 | $47,458 |
| E.R. Squibb & Sons, L.L.C. | 28 | $7,249 |
| Neurocrine BioSciences, Inc. | 38 | $615 |
| Otsuka America Pharmaceutical, Inc. | 41 | $564 |
| Janssen Pharmaceuticals, Inc | 26 | $414 |
| Teva Pharmaceuticals USA, Inc. | 18 | $316 |
| Vanda Pharmaceuticals Inc. | 11 | $253 |
| Alkermes, Inc. | 13 | $150 |
| Axsome Therapeutics, Inc. | 7 | $128 |
| ABBVIE INC. | 4 | $80 |
Products named: CAPLYTA, COBENFY, INGREZZA, REXULTI, INVEGA SUSTENNA, AUSTEDO XR, UZEDY, ARISTADA.
Industry payments across KS — which companies pay providers there.
